Insider Transactions and Market Context for Oruka Therapeutics
According to filings with the SEC, Arjun Agarwal, Senior Vice President of Finance at Oruka Therapeutics (NASDAQ: ORKA), was involved in notable stock transactions on May 18, 2026. These activities encompass both selling common stock and acquiring shares through the exercise of employee stock options.
Mr. Agarwal sold a total amount of $607,806 worth of Oruka Therapeutics common stock. The weighted average prices across these sales ranged between $58.3449 and $61.1606 per share. The sales specifically involved the disposal of 10,290 shares of ORKA common stock.
Crucially, these divestitures were managed under a Rule 10b5-1 trading plan that Mr. Agarwal had previously established on February 11, 2026. Concurrently with the sales, he increased his holdings by acquiring common stock valued at $225,596 through the exercise of employee stock options. The exercise prices for these newly acquired shares varied from $12.50 to $34.39 per share.
The transactions reveal a mix of activities: 4,190 shares were sold at prices ranging from $57.72 to $58.71, while an additional 700 shares were transacted between prices of $60.82 and $61.76.
On the same date, Mr. Agarwal acquired a total of 7,833 common shares by exercising options. This acquisition included 2,000 shares utilizing an exercise price of $12.50, and another 5,833 shares at an exercise price of $34.39.
These acquired options are subject to vesting schedules: they vest monthly as 1/48th of the underlying shares from their respective grant dates of January 1, 2025, and January 1, 2026.
Following these transactions on May 18, 2026, Mr. Agarwal's direct holdings amounted to 16,406 shares of Oruka Therapeutics common stock. Furthermore, he retains unexercised employee stock options totaling 118,000 shares with an exercise price of $12.50 and 64,167 shares with an exercise price of $34.39.
Market Performance and Valuation Metrics
The timing of these insider sales occurs as ORKA shares have demonstrated significant appreciation. Over the last year, the stock has surged by more than 515%, currently trading at $58.34 per share with a reported market capitalization of $3.54 billion.
Market analysis from InvestingPro indicates that the stock may be overvalued relative to its Fair Value, noting its placement among companies listed on the Most Overvalued list. Despite this valuation assessment, the company has shown strong upward momentum in recent periods. Specifically, InvestingPro Tips highlight robust returns over the last three and six months, reporting gains of 125% during the latter half-year period.
In terms of operational profitability, Oruka Therapeutics has not been profitable over the preceding twelve months. However, this lack of recent profit is counterbalanced by positive analyst sentiment; seven analysts have recently revised their earnings estimates upward for the upcoming reporting period.
Corporate Developments and Clinical Progress
Beyond insider activity, Oruka Therapeutics has advanced several key corporate developments that define its current financial structure and pipeline. The company previously announced encouraging interim results from its EVERLAST-A Phase 2a trial involving ORKA-001, a treatment designed for moderate-to-severe plaque psoriasis.
The clinical trial data indicated strong efficacy, showing that 63.5% of participants achieved a PASI 100 score by Week 16, alongside achieving significant secondary endpoint goals. These positive medical outcomes have attracted immediate attention from the investment community, leading to upward revisions in price targets for Oruka Therapeutics. Specifically, H.C. Wainwright raised its price target to $120 while maintaining a Buy rating, and Clear Street increased its price target to $131, also issuing a Buy rating.
Financially, the company is actively securing capital through public offerings. Oruka Therapeutics has priced an upsized public offering of 9,660,000 shares at $72.50 per share, which is expected to generate approximate gross proceeds of $700.4 million. This transaction follows a previous announcement regarding a $500 million stock offering, which consisted of common stock and pre-funded warrants. The company has also provided underwriters with an option lasting 30 days to purchase supplementary shares at the established offering price.
Analysis Summary
The reported transactions paint a picture of internal liquidity management by senior leadership (Mr. Agarwal) while simultaneously pointing to significant external validation through positive clinical data and substantial capital raises. The market is reacting strongly to the scientific milestones, driving high valuations despite current operational losses.